Perrigo (PRGO) PT Set at $105.00 by Canaccord Genuity
Perrigo (NYSE:PRGO) has been assigned a $105.00 price target by investment analysts at Canaccord Genuity in a report released on Monday. The brokerage currently has a “buy” rating on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 26.04% from the stock’s current price.
Several other brokerages also recently commented on PRGO. Cantor Fitzgerald reiterated a “buy” rating and issued a $107.00 target price on shares of Perrigo in a report on Thursday, November 9th. Royal Bank of Canada upgraded shares of Perrigo from an “underperform” rating to a “sector perform” rating and increased their target price for the company from $64.00 to $86.00 in a report on Friday, November 10th. Morgan Stanley increased their target price on shares of Perrigo from $79.00 to $92.00 and gave the company an “equal weight” rating in a report on Friday, November 10th. Wells Fargo & Co increased their target price on shares of Perrigo to $90.00 and gave the company a “market perform” rating in a report on Friday, November 10th. Finally, Jefferies Group reiterated a “hold” rating and issued a $81.00 target price on shares of Perrigo in a report on Friday, November 10th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $92.44.
Perrigo (NYSE PRGO) opened at $83.31 on Monday. Perrigo has a 12 month low of $63.68 and a 12 month high of $95.93. The firm has a market cap of $11,687.78, a price-to-earnings ratio of 99.18, a price-to-earnings-growth ratio of 1.78 and a beta of 0.82. The company has a quick ratio of 1.40, a current ratio of 1.96 and a debt-to-equity ratio of 0.53.
In other Perrigo news, VP Todd W. Kingma sold 1,500 shares of the stock in a transaction dated Thursday, December 28th. The shares were sold at an average price of $88.52, for a total transaction of $132,780.00. Following the completion of the transaction, the vice president now owns 19,565 shares in the company, valued at $1,731,893.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Wesolowski bought 700 shares of the business’s stock in a transaction on Thursday, December 14th. The shares were acquired at an average price of $85.80 per share, with a total value of $60,060.00. The disclosure for this purchase can be found here. Insiders have sold 3,450 shares of company stock valued at $302,951 in the last 90 days. 6.90% of the stock is currently owned by corporate insiders.
A number of large investors have recently modified their holdings of the business. Crossmark Global Holdings Inc. boosted its position in Perrigo by 8.3% during the fourth quarter. Crossmark Global Holdings Inc. now owns 7,741 shares of the company’s stock worth $675,000 after purchasing an additional 595 shares during the period. New Mexico Educational Retirement Board boosted its position in Perrigo by 5.0% during the fourth quarter. New Mexico Educational Retirement Board now owns 12,700 shares of the company’s stock worth $1,107,000 after purchasing an additional 600 shares during the period. Norinchukin Bank The boosted its position in Perrigo by 6.1% during the fourth quarter. Norinchukin Bank The now owns 10,472 shares of the company’s stock worth $913,000 after purchasing an additional 601 shares during the period. Brown Advisory Inc. boosted its position in Perrigo by 10.9% during the third quarter. Brown Advisory Inc. now owns 6,245 shares of the company’s stock worth $529,000 after purchasing an additional 613 shares during the period. Finally, Nomura Asset Management Co. Ltd. boosted its position in Perrigo by 4.3% during the third quarter. Nomura Asset Management Co. Ltd. now owns 18,350 shares of the company’s stock worth $1,553,000 after purchasing an additional 749 shares during the period. Hedge funds and other institutional investors own 78.23% of the company’s stock.
Perrigo Company plc is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, infant formulas, nutritional products, animal health, dietary supplements, active pharmaceutical ingredients (API), and medical diagnostic products, and Multiple Sclerosis drug Tysabri.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.